A subsequent trial in France, SU.VI.MAX (n = 5,141, 103 prostate cancer cases), reported that daily supplementation with 30 mg α-tocopherol for 8 years (along with other antioxidants in the combination supplement) significantly reduced the incidence of prostate cancer among men with normal PSA at baseline (HR = 0.52, 95% CI 0.29–0.92) [44]. Here, KLK3 is linked to Familial prostate cancer.